Business Description
DiaMedica Therapeutics Inc
NAICS : 325412
SIC : 3741
ISIN : CA25253X1087
Description
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 139.32 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 6.4 | |||||
| 3-Year EPS without NRI Growth Rate | 8.4 | |||||
| 3-Year FCF Growth Rate | 0.7 | |||||
| 3-Year Book Growth Rate | -1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -10.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.44 | |||||
| 9-Day RSI | 54.85 | |||||
| 14-Day RSI | 54.53 | |||||
| 6-1 Month Momentum % | 65.61 | |||||
| 12-1 Month Momentum % | 94.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 17.82 | |||||
| Quick Ratio | 17.82 | |||||
| Cash Ratio | 17.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.5 | |||||
| Shareholder Yield % | 0.03 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -37.38 | |||||
| ROA % | -35.49 | |||||
| ROIC % | -294.08 | |||||
| 3-Year ROIIC % | -1436.65 | |||||
| ROC (Joel Greenblatt) % | -4564.44 | |||||
| ROCE % | -41.79 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.5 | |||||
| Price-to-Tangible-Book | 3.5 | |||||
| EV-to-EBIT | -6.01 | |||||
| EV-to-EBITDA | -6.01 | |||||
| EV-to-FCF | -6.79 | |||||
| Price-to-Net-Current-Asset-Value | 3.61 | |||||
| Price-to-Net-Cash | 3.67 | |||||
| Earnings Yield (Greenblatt) % | -16.64 | |||||
| FCF Yield % | -10.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DMAC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
DiaMedica Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.53 | ||
| Beta | 0.83 | ||
| Volatility % | 38.27 | ||
| 14-Day RSI | 54.53 | ||
| 14-Day ATR ($) | 0.183163 | ||
| 20-Day SMA ($) | 4.37975 | ||
| 12-1 Month Momentum % | 94.88 | ||
| 52-Week Range ($) | 2.12 - 4.95 | ||
| Shares Outstanding (Mil) | 42.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
DiaMedica Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
DiaMedica Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
DiaMedica Therapeutics Inc Frequently Asked Questions
What is DiaMedica Therapeutics Inc(DMAC)'s stock price today?
The current price of DMAC is $4.37. The 52 week high of DMAC is $4.95 and 52 week low is $2.12.
When is next earnings date of DiaMedica Therapeutics Inc(DMAC)?
The next earnings date of DiaMedica Therapeutics Inc(DMAC) is 2024-11-13 Est..
Does DiaMedica Therapeutics Inc(DMAC) pay dividends? If so, how much?
DiaMedica Therapeutics Inc(DMAC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers